| Dr Theodore T Tsaltas, MD | |
|
810 Saint Vincents Dr, Birmingham, AL 35205 | |
| (205) 930-2456 | |
| (205) 930-2469 |
| Full Name | Dr Theodore T Tsaltas |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 810 Saint Vincents Dr, Birmingham, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679594881 | NPI | - | NPPES |
| 3811261 | Medicaid | TN |
| Entity Name | Obhg Tennessee, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285924977 PECOS PAC ID: 1850566514 Enrollment ID: O20111207000456 |
News Archive
A new study has found that genes cause about 1 in 10 cases of chronic kidney disease in adults, and identifying the responsible gene has a direct impact on treatment for most of these patients.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
With the launch of the country's first ever commercial genetic test for type 2 diabetes, Indians will now have access to clinically relevant and cost effective genetic risk assessment services. NutraGene, a Delhi based genomics company that launched the tests believes that its type 2 diabetes genetic test will provide physicians an effective tool in assessing the risk of diabetes in the Indian population and will help in implementing personalized prevention and management strategies.
Scientists from Trinity College Dublin have developed a new gene therapy approach that offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Theodore T Tsaltas, MD 810 Saint Vincents Dr, Birmingham, AL 35205-1601 Ph: (205) 930-2456 | Dr Theodore T Tsaltas, MD 810 Saint Vincents Dr, Birmingham, AL 35205 Ph: (205) 930-2456 |
News Archive
A new study has found that genes cause about 1 in 10 cases of chronic kidney disease in adults, and identifying the responsible gene has a direct impact on treatment for most of these patients.
Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.
With the launch of the country's first ever commercial genetic test for type 2 diabetes, Indians will now have access to clinically relevant and cost effective genetic risk assessment services. NutraGene, a Delhi based genomics company that launched the tests believes that its type 2 diabetes genetic test will provide physicians an effective tool in assessing the risk of diabetes in the Indian population and will help in implementing personalized prevention and management strategies.
Scientists from Trinity College Dublin have developed a new gene therapy approach that offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe.
› Verified 9 days ago
James R Dollar, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 48 Medical Park Dr E, Suite 355, Birmingham, AL 35235 Phone: 205-838-3036 Fax: 205-838-5832 | |
Richard Own Burney, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1700 6th Ave S, Birmingham, AL 35233 Phone: 205-996-3130 | |
Sarah Fort Whitehead, M.D. Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 2006 Brookwood Med Ctr Dr Ste 700, Birmingham, AL 35209 Phone: 205-397-1286 Fax: 205-397-1340 | |
Kimberly Hoover, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Percy Charles Hudson, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 806 Saint Vincents Dr, Suite 430, Birmingham, AL 35205 Phone: 205-939-2806 | |
Isuzu Meyer, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Sarah Dunk, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 |